Mahesh Anantha-Narayanan1, Dixitha Anugula2, Nagarjuna R Gujjula2, Yogesh N V Reddy3, Janani Baskaran1, Manu Kaushik4, Venkata M Alla2, Ganesh Raveendran1. 1. Division of Cardiovascular Disease, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. 2. Division of Cardiology, CHI Health Creighton University Medical Center, Omaha, NE, USA. 3. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. 4. Division of Cardiovascular Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Abstract
BACKGROUND: Bivalirudin has been shown to be associated with less major bleeding than heparin in patients undergoing percutaneous coronary intervention (PCI); but the confounding effect of concomitant glycoprotein IIb/IIIa inhibitors (GPI) limits meaningful comparison. We performed a systematic review and meta-analysis to compare bivalirudin to heparin, with and without adjunctive GPI in PCI. METHODS: We searched PubMed, Cochrane, EMBASE, CINAHL and WOS from January 2000 to December 2017 for clinical trials comparing bivalirudin to heparin, with and without adjunctive GPI during PCI. Cochrane's Q statistics were used to determine heterogeneity. Random effects model was used. RESULTS: Twenty-six comparison groups (22 original studies and 4 subgroup analyses) with 53,364 patients were included. Mean follow-up was 192±303 days. There was no difference between the two groups in all-cause mortality [risk ratio (RR: 0.93; 95% CI: 0.82-1.05, P=0.260), target vessel revascularization (TVR) (RR: 1.17; 95% CI: 0.93-1.46, P=0.174) or stroke (RR: 0.91; 95% CI: 0.71-1.18, P=0.490). Major bleeding was lower in the bivalirudin group with concomitant GPI in one or both arms (RR: 0.64; 95% CI: 0.53-0.77, P<0.001) and without (RR: 0.71; 95% CI: 0.51-0.99, P=0.041) provisional or routine GPIs. Bivalirudin appeared to have a higher risk of stent thrombosis (RR: 1.32; 95% CI: 1.04-1.68, P=0.022) and a trend towards more myocardial infarction (RR: 1.12; 95% CI: 0.98-1.28, P=0.098) though without statistical significance. However, exclusion of studies with GPI showed no difference in stent thrombosis or myocardial infarction with bivalirudin. CONCLUSIONS: Bivalirudin is associated with less major bleeding compared to heparin, regardless of GPI use. The lower anticoagulant effect of bivalirudin is linked with higher stent thrombosis and a trend towards more MI, however a confounding effect of GPI use in the heparin arm cannot be excluded.
BACKGROUND: Bivalirudin has been shown to be associated with less major bleeding than heparin in patients undergoing percutaneous coronary intervention (PCI); but the confounding effect of concomitant glycoprotein IIb/IIIa inhibitors (GPI) limits meaningful comparison. We performed a systematic review and meta-analysis to compare bivalirudin to heparin, with and without adjunctive GPI in PCI. METHODS: We searched PubMed, Cochrane, EMBASE, CINAHL and WOS from January 2000 to December 2017 for clinical trials comparing bivalirudin to heparin, with and without adjunctive GPI during PCI. Cochrane's Q statistics were used to determine heterogeneity. Random effects model was used. RESULTS: Twenty-six comparison groups (22 original studies and 4 subgroup analyses) with 53,364 patients were included. Mean follow-up was 192±303 days. There was no difference between the two groups in all-cause mortality [risk ratio (RR: 0.93; 95% CI: 0.82-1.05, P=0.260), target vessel revascularization (TVR) (RR: 1.17; 95% CI: 0.93-1.46, P=0.174) or stroke (RR: 0.91; 95% CI: 0.71-1.18, P=0.490). Major bleeding was lower in the bivalirudin group with concomitant GPI in one or both arms (RR: 0.64; 95% CI: 0.53-0.77, P<0.001) and without (RR: 0.71; 95% CI: 0.51-0.99, P=0.041) provisional or routine GPIs. Bivalirudin appeared to have a higher risk of stent thrombosis (RR: 1.32; 95% CI: 1.04-1.68, P=0.022) and a trend towards more myocardial infarction (RR: 1.12; 95% CI: 0.98-1.28, P=0.098) though without statistical significance. However, exclusion of studies with GPI showed no difference in stent thrombosis or myocardial infarction with bivalirudin. CONCLUSIONS: Bivalirudin is associated with less major bleeding compared to heparin, regardless of GPI use. The lower anticoagulant effect of bivalirudin is linked with higher stent thrombosis and a trend towards more MI, however a confounding effect of GPI use in the heparin arm cannot be excluded.
Authors: A Michael Lincoff; John A Bittl; Neal S Kleiman; Ian J Sarembock; J Daniel Jackman; Sameer Mehta; Mark A Tannenbaum; Alan L Niederman; William B Bachinsky; J Tift-Mann; H Graham Parker; Dean J Kereiakes; Robert A Harrington; Frederick Feit; Elizabeth S Maierson; Derek P Chew; Eric J Topol Journal: Am J Cardiol Date: 2004-05-01 Impact factor: 2.778
Authors: Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran Journal: Lancet Date: 2011-06-12 Impact factor: 79.321
Authors: M Moscucci; K A A Fox; Christopher P Cannon; W Klein; José López-Sendón; G Montalescot; K White; R J Goldberg Journal: Eur Heart J Date: 2003-10 Impact factor: 29.983
Authors: Giuseppe Patti; Vincenzo Pasceri; Luca D'Antonio; Andrea D'Ambrosio; Michele Macrì; Giordano Dicuonzo; Giuseppe Colonna; Antonio Montinaro; Germano Di Sciascio Journal: Am J Cardiol Date: 2012-05-12 Impact factor: 2.778
Authors: Uwe Zeymer; Arnoud van 't Hof; Jennifer Adgey; Lutz Nibbe; Peter Clemmensen; Claudio Cavallini; Jurrien ten Berg; Pierre Coste; Kurt Huber; Efthymios N Deliargyris; Jonathan Day; Debra Bernstein; Patrick Goldstein; Christian Hamm; Philippe Gabriel Steg Journal: Eur Heart J Date: 2014-05-21 Impact factor: 29.983
Authors: Łukasz Kołtowski; Jacek Legutko; Krzysztof J Filipiak; Artur Dziewierz; Stanisław Bartuś; Paweł Buszman; Piotr Buszman; Dariusz Ciećwierz; Maciej Dąbrowski; Sławomir Dobrzycki; Robert Gil; Jarosław Gorący; Marek Grygier; Miłosz Jaguszewski; Janusz Kochman; Jacek Kubica; Wiktor Kuliczkowki; Piotr Lodziński; Andrzej Ochała; Krzysztof Reczuch; Adam Witkowski; Wojciech Wojakowski; Jarosław Wójcik; Dariusz Dudek Journal: Cardiol J Date: 2019 Impact factor: 2.737
Authors: Mario Gaudino; Dominick J Angiolillo; Antonino Di Franco; Davide Capodanno; Faisal Bakaeen; Michael E Farkouh; Stephen E Fremes; David Holmes; Leonard N Girardi; Sunao Nakamura; Stuart J Head; Seung-Jung Park; Michael Mack; Patrick W Serruys; Marc Ruel; Gregg W Stone; Derrick Y Tam; Michael Vallely; David P Taggart Journal: J Am Heart Assoc Date: 2019-06-27 Impact factor: 5.501